Get the Stockscreener App
0.0743
3.63%
0.0026
Clearmind Medicine Inc stock is traded at $0.0743, with a volume of 11.00M.
It is up +3.63% in the last 24 hours and down -76.06% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.0717
Open:
$0.079
24h Volume:
11.00M
Relative Volume:
0.87
Market Cap:
$4.46M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.00174
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-42.45%
1M Performance:
-76.06%
6M Performance:
-91.32%
1Y Performance:
-94.91%
1-Day Range:
$0.0716
$0.08
1-Week Range:
$0.0661
$0.1255
52-Week Range:
$0.0661
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.0743 | 4.30M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment - The Manila Times
Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement - marketscreener.com
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - The Manila Times
Clearmind Medicine regains compliance with Nasdaq listing rule By Investing.com - Investing.com Canada
Clearmind regains compliance with Nasdaq minimum equity rule - Investing.com
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity - Quiver Quantitative
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum ... | Associated Press | syndication news - Enidnews.com
Clearmind Medicine To Implement 1-for-40 Reverse Stock Split Next Week - Nasdaq
Why Did Clearmind Medicine Shares Plunge 29% After Hours? - Benzinga
Clearmind Medicine to enact 1-for-40 reverse share split; shares down - MSN
Clearmind Medicine to implement 1-for-40 reverse stock split By Investing.com - Investing.com Australia
Clearmind Medicine to implement 1-for-40 reverse stock split - Investing.com
Clearmind Medicine Inc. Announces 1-for-40 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine Announces 1-for-40 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-for-40 Reverse Share Split | Associated Press | syndication news - Enidnews.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification - marketscreener.com
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine Shares Surge After Securing Final Approval for AUD Drug Trial Site - MSN
Clearmind Medicine announces receipt of Nasdaq minimum bid price notification - MSN
Clearmind Medicine reports regaining Nasdaq equity compliance after financings - Investing.com
Clearmind Medicine reports regaining Nasdaq equity compliance after financings By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Receives Nasdaq Compliance Notice Regarding Minimum Bid Price Requirement - Quiver Quantitative
Clearmind Medicine stock drops after Nasdaq compliance notice By Investing.com - Investing.com South Africa
Clearmind Medicine stock drops after Nasdaq compliance notice - Investing.com
Is Clearmind Medicine Inc. stock near bottom after declineWeekly Loss Report & High Return Stock Watch Alerts - Newser
Will Clearmind Medicine Inc. stock outperform tech sector in 2025July 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
How Clearmind Medicine Inc. (CWY0) stock behaves under inflation pressureWeekly Gains Report & Low Risk Entry Point Tips - Newser
Clearmind Medicine Inc files for offering of up to 16 million common sharesSEC filing - marketscreener.com
What MACD trends signal for Clearmind Medicine Inc. (CWY0) stock - Newser
Is Clearmind Medicine Inc. (CWY0) stock a good hedge against inflationJuly 2025 Levels & Risk Managed Investment Signals - Newser
Can Clearmind Medicine Inc. (CWY0) stock double in coming yearsJuly 2025 Earnings & Verified High Yield Trade Plans - Newser
Clearmind enrolls first participant in AUD trial at Hadassah Medical - Investing.com India
Clearmind enrolls first participant in AUD trial at Hadassah Medical By Investing.com - Investing.com Canada
Clearmind Medicine advances CMND-100 to dosing phase at Hadassah Medical Center - marketscreener.com
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Clearmind Medicine (CMND) Stock Analysis Report | Financials & Insights - Benzinga
Clearmind reports positive results in alcohol disorder treatment trial By Investing.com - Investing.com Nigeria
Clearmind reports positive results in alcohol disorder treatment trial - Investing.com
Clearmind Medicine Inc. Reports Key Milestones in Phase I/IIa Trial for Alcohol Use Disorder Treatment CMND-100 - Quiver Quantitative
Clearmind advances alcoholism treatment with positive data, DSMB approval, and new trial site - marketscreener.com
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial - The Manila Times
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):